Beijing Olympics Deal A Blow To Indian Drug Makers As API Prices Rise
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Indian drug makers are faced with a severe shortage of key active pharmaceutical ingredients as the Chinese government clamps down on the manufacture and movement of chemicals known to pollute the environment. As such, exports of known hazardous chemicals and APIs to India from China have dried up leading to shortage and a spurt in raw material prices
You may also be interested in...
Drug Manufacturers Should Expect No Relief From China’s Rising API Prices
SHANGHAI - API prices in China have increased since the end of last year, and prices are expected to continue to rise with the addition of new costs associated with stronger environmental protection standards, according to analysts
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).